Cardiac Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Department of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University Nuremberg, Nuremberg, Germany.
Artif Organs. 2022 May;46(5):763-774. doi: 10.1111/aor.14130. Epub 2021 Dec 12.
Extracorporeal carbon dioxide removal (ECCO R) provides respiratory support to patients suffering from hypercapnic respiratory failure by utilizing an extracorporeal shunt and gas exchange membrane to remove CO from either the venous (VV-ECCO R) or arterial (AV-ECCO R) system before return into the venous site. AV-ECCO R relies on the patient's native cardiac function to generate pressures needed to deliver blood through the extracorporeal circuit. VV-ECCO R utilizes a mechanical pump and can be used to treat patients with inadequate native cardiac function. We sought to evaluate the existing evidence comparing the subgroups of patients supported on VV and AV-ECCO R devices.
A literature search was performed to identify all relevant studies published between 2000 and 2019. Demographic information, medical indications, perioperative variables, and clinical outcomes were extracted for systematic review and meta-analysis.
Twenty-five studies including 826 patients were reviewed. 60% of patients (497/826) were supported on VV-ECCO R. The most frequent indications were acute respiratory distress syndrome (ARDS) [69%, (95%CI: 53%-82%)] and chronic obstructive pulmonary disease (COPD) [49%, (95%CI: 37%-60%)]. ICU length of stay was significantly shorter in patients supported on VV-ECCO R compared to AV-ECCO R [15 (95%CI: 7-23) vs. 42 (95%CI: 17-67) days, p = 0.05]. In-hospital mortality was not significantly different [27% (95%CI: 18%-38%) vs. 36% (95%CI: 24%-51%), p = 0.26].
Both VV and AV-ECCO R provided clinically meaningful CO removal with comparable mortality.
体外二氧化碳去除(ECCO R)通过利用体外分流和气体交换膜从静脉(VV-ECCO R)或动脉(AV-ECCO R)系统中去除 CO,为患有高碳酸血症性呼吸衰竭的患者提供呼吸支持,然后将其返回到静脉部位。AV-ECCO R 依赖于患者自身的心脏功能来产生输送血液通过体外回路所需的压力。VV-ECCO R 使用机械泵,可用于治疗自身心功能不足的患者。我们旨在评估比较接受 VV 和 AV-ECCO R 设备支持的患者亚组的现有证据。
进行了文献检索,以确定 2000 年至 2019 年期间发表的所有相关研究。系统评价和荟萃分析提取了人口统计学信息、医疗适应证、围手术期变量和临床结局。
共审查了 25 项研究,包括 826 名患者。60%的患者(497/826)接受 VV-ECCO R 支持。最常见的适应证是急性呼吸窘迫综合征(ARDS)[69%(95%CI:53%-82%)]和慢性阻塞性肺疾病(COPD)[49%(95%CI:37%-60%)]。与 AV-ECCO R 相比,接受 VV-ECCO R 支持的患者 ICU 住院时间明显缩短[15(95%CI:7-23)天 vs. 42(95%CI:17-67)天,p=0.05]。院内死亡率无显著差异[27%(95%CI:18%-38%)vs. 36%(95%CI:24%-51%),p=0.26]。
VV 和 AV-ECCO R 均提供了具有临床意义的 CO 去除作用,死亡率相当。